How Human Gene Therapy Has Treated Brain Cancer Since 2000

Abstract

Disorders and diseases can be treated with a variety of methods, including conventional medicine and human gene therapy. The primary distinction between these two methods lies in their respective approaches.  Biomedical engineering is an emerging field that seeks to focus on the advances to improve human health and health care with genetic engineering, which is a field involving genetics,  as a primary method as one of the subfields. Human gene therapy, falling underneath the field of genetic engineering, targets the root cause of the ailment, resulting in long-lasting effects. Human gene therapy has been accessible since the early 1970s, with a primary focus on the treatment of genetic disorders and diseases (1992). Scientists have made significant efforts to address a wide range of ailments, including various types of cancer, sickle cell disease, hemophilia, and others. This article specifically highlights the remarkable accomplishments of human gene therapy treatments for animal models of brain cancer over the past 25 years. Through an extensive examination of existing literature, we review an article where mice were observed using in vivo experimental work when evaluating baculoviral vectors as a potential solution for brain cancer. Furthermore, we review the various techniques employed in human gene therapy, thereby ascertaining their potential applicability as a viable treatment modality. Based on this data, the author has concluded that human gene therapy, facilitated by the utilization of recombinant DNA technology, has effectively treated brain cancer.